Table 1.
Patient and transplant characteristics.
| Patient | Age (years) | Underlying disease | Previous HSCT | Donor | Source of stem cells | Receptor/Donor CMV serostatus | Conditioning regimen | In vivo T-cell depletion | Ex vivo T-cell depletion | aGVHD (grade) | Steroids >0.5 mg/kg/day | Lymphocyte count ×10E9/L (total/CD4) at CMVIG prescription | Days from HSCT to first CMV reactivation | Other viral infections |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ≥5–10 | Amegakaryocytic thrombocytopenia | Yes | Haploidentical | BM | R+/D+ | RIC | ATG | No | 0 | No | 0/0 | 19 | AdV, EBV, HHV-6 |
| 2 | ≥10–18 | Lymphoblastic lymphoma T, CR-2 | Yes | Haploidentical | PB | R+/D+ | RIC | ATG | Yes | 2 | Yes | 0.8/0.1 | 14 | AdV, EBV |
| 3 | 0–5 | PID (mut. ARPC1b) | No | MMUD | BM | R+/D− | RIC | ATG | No | 0 | No | 0/0 | 8 | No |
| 4 | ≥10–18 | ALL-B, CR-2 | No | MMUD | BM | R+/D− | MAC | ATG | No | 1 | No | 0.2/0.01 | 26 | AdV, EBV |
| 5 | ≥10–18 | ALL-B, CR-1 | No | MMUD | BM | R+/D+ | MAC | ATG | No | 1 | Yes | 0.2/0.05 | 25 | EBV |
| 6 | ≥10–18 | Fanconi anemia | No | MUD | PB | R+/D+ | RIC | ATG | Yes | 0 | No | 0.7/0.01 | 20 | No |
| 7 | ≥10–18 | ALL-T, CR-2 | No | MUD | PB | R+/D− | MAC | ATG | No | 2 | Yes | 0.5.0.04 | 29 | AdV, EBV, HHV-6 |
| 8 | 0–5 | Thalassemia maior | No | MSD | CB | R+/D+ | MAC | No | No | 2 | Yes | 0.7/0.05 | 25 | No |
| 9 | ≥10–18 | ALL-B, CR-1 | No | MMUD | PB | R+/D+ | MAC | ATG | No | 4 | Yes | 0.3/0.04 | 24 | AdV, EBV |
| 10 | 0–5 | Chronic granulomatous disease | No | MUD | BM | R+/D+ | RIC | Alemtuzumab | No | 2 | Yes | 0.1/0.01 | 30 | EBV, BK |
| 11 | ≥10–18 | ALL-B, CR-1 | No | MUD | BM | R+/D+ | MAC | ATG | No | 1 | Yes | 2.4/0.5 | 50 | AdV, EBV |
| 12 | ≥5–10 | ALL-B, CR-2 | No | MUD | BM | R+/D− | MAC | ATG | No | 1 | No | 0.05/0.05 | 21 | No |
| 13 | ≥10–18 | Chronic mucocutaneous candidiasis | No | MMUD | PB | R+/D+ | RIC | ATG | No | 2 | Yes | 0/0 | 1 | BK, HHV-6, Parvovirus B-19 |
| 14 | ≥10–18 | Chronic granulomatous disease | No | MUD | BM | R+/D− | RIC | Alemtuzumab | No | 2 | Yes | 0.2/0.04 | 18 | BK |
| 15 | ≥10–18 | ALL-B, CR-1 | No | MMUD | PB | R+/D+ | MAC | ATG | No | 2 | Yes | 0.2/0.02 | 25 | EBV, BK |
F, female; M, male; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; MSD, matched sibling donor; BM, bone marrow; PB, peripheral blood; CB, cord blood; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; ATG, anti-thymocyte globulin; aGVHD, acute graft-vs.-host disease; EBV, Epstein-Barr virus; BK, BK virus; AdV, adenovirus; HHV-6, human herpesvirus 6.